$MODD

Modular Medical (MODD) director receives fully vested stock options

Modular Medical, Inc. director and ten percent owner C. Frank Morgan received fully vested stock options to purchase an additional 312 shares of common stock as compensation. The options were granted under the company’s Outside Director Compensation Plan with an exercise price of $4.55 per share and are immediately exercisable, reflecting a neutral filing impact and sentiment. This Form 4 filing details two separate grants for 62 and 250 shares, both expiring on March 31, 2036.

Original reporting
Published Apr 10, 2026, 4:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 10, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MODD
Neutral
medium confidence
Mentioned
$MODD
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$MODDNeutralLow
01

Why it matters

The event is standard and unlikely to cause significant stock price movement.

02

Market read

Low; primarily relevant to company insiders and long-term investors.

03

What to watch

Market reaction could be minimal; other external factors are more likely to influence the stock price.

Timing: long-term

Background

Modular Medical, Inc. is issuing stock options to its director as part of compensation, a common practice to align interests.

Company-level read

Ticker impact

$MODDNeutralMedium confidence
Context

The news pertains to insider stock option grants at Modular Medical, Inc., which could influence investor sentiment and stock price.

Expected impact

Minimal to no immediate price movement expected

Evidence & confidence

The grant is a standard compensation event with no unusual features; market reaction is likely limited.

Market effects

Limited; the event pertains to executive compensation and is unlikely to affect sector-wide sentiment.

Negligible; specific to company insiders.

Negligible; no broader market implications.

Counterpoint

Some traders might interpret insider stock option grants as a sign of insider confidence, potentially positive for the stock in the long term.

Key entities

  • Modular Medical, Inc.

    A medical device company involved in healthcare solutions.

Related articles

$MODDHigh

Modular Medical stock rises after securing PBM contract

Modular Medical Inc (MODD) shares rose 2.3% after securing a contract with a national U.S. pharmacy benefit manager, making its Pivot insulin delivery system available through the PBM. The company aims to broaden patient access to its Pivot tubeless patch pump, a wearable insulin delivery platform for diabetes management.

$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

$CMGMed

2 Monster Stocks to Buy and Hold for at Least the Next 5 Years

Chipotle (CMG) expanded internationally via partnerships, opening in South Korea and Mexico. It plans further Asian expansion. Domestically, it relaunched rewards to combat softer sales. e.l.f. Beauty (ELF) launches rhode in Europe, targeting a large existing social media following. Both companies aim for long-term growth through international markets.

$PEPMed

Publicis wins PepsiCo global media business

Publicis Groupe won PepsiCo’s global media business, consolidating strategy and technology under a new 'One PepsiCo' structure. PepsiCo spent $5.4B on marketing in 2025, including $3.4B on advertising. Publicis may withdraw from Coca-Cola’s media review. PepsiCo aims to modernize media operations with AI and data.

$LHXHighAI 9/10

L3Harris, with Northampton plant, lands historic $4.7B Patriot missile contract

L3Harris Technologies secured a $4.7 billion, seven-year contract with Lockheed Martin for PAC-3 missile propulsion systems. The deal supports large-scale production of interceptors for tactical and cruise missiles. L3Harris, valued at $60B-$65B, did not disclose if work will occur at its Northampton plant. The contract aligns with a broader $58.6B DoD agreement to increase PAC-3 production.